Clinical Trials Logo

Clinical Trial Summary

Investigate the preprocedural predictors of left ventricular systolic function Recovery after TAVR


Clinical Trial Description

Calcific aortic stenosis (AS) is the most common valve disease in the western world requiring intervention,Although Surgical Aortic Valve Replacement (SAVR) was considered as the first therapeutic method, approximately one-third of AS patients cannot undergo SAVR due to its' high risk or contraindication. Since Transcatheter Aortic Valve Replacement (TAVR)was performed for the first time in 2002,TAVR has emerged as a growing prevalent treatment on severe symptomatic AS with the procedure initially performed on the inoperable patients with intermediate and high risks. Recently, the Food and Drug Administration had approved it on low-risk symptomatic subjects. AS has to be considered a disease of the left ventricle (LV) rather than purely affecting the aortic valve, Approximately one-third of patients with severe symptomatic AS have LV systolic dysfunction . Recovery of LV ejection fraction (LVEF) is associated with improvements in clinical outcomes after TAVR as shown by a lot of studies. The Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated that recovery of LV function in patients with severe symptomatic AS and LV systolic dysfunction who underwent TAVR, occurs in 40% to 50% of patients . Higher trans-aortic mean pressure gradient , less LV hypertrophy, Less LV fibrosis and absence of AF are predictors of recovery of LV function after TAVR . However, there is still a scanty data about the predictors of LV function recovery after TAVR. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05069168
Study type Observational
Source Assiut University
Contact Helen sami Anwar
Phone 01013934903
Email [email protected]
Status Not yet recruiting
Phase
Start date April 1, 2022
Completion date December 30, 2023